Evidence map›Paper›PMID 35032406›Full record

ReviewAdvanced healthcare materials2022

PLGA's Plight and the Role of Stealth Surface Modification Strategies in Its Use for Intravenous Particulate Drug Delivery.

Violet V Sheffey, Emily B Siew, Eden E L Tanner, Omolola Eniola-Adefeso

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Violet V SheffeyMacromolecular Science and Engineering Program, University of Michigan Ann Arbor, NCRC Building 28, 2800 Plymouth Rd., Ann Arbor, MI, 48109, USA.
Emily B SiewDepartment of Chemical Engineering, University of Michigan Ann Arbor, NCRC 28, 2800 Plymouth Rd., Ann Arbor, MI, 48109, USA.
Eden E L TannerDepartment of Chemistry and Biochemistry, University of Mississippi, 179 Coulter Hall, University, MS, 38677, USA.
Omolola Eniola-AdefesoMacromolecular Science and Engineering Program, University of Michigan Ann Arbor, NCRC Building 28, 2800 Plymouth Rd., Ann Arbor, MI, 48109, USA.ORCID 0000-0002-8728-6608

Funding

Role of carrier plasma protein corona in their vascular wall localizationR01HL115138 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ENIOLA-ADEFESO, OMOLOLA · 2012 to 2016
$1.9M
Development of PolyAspirin Particles for Therapeutic Intervention in ALI/ARDS via the Passive Restraint of Neutrophil FunctionR01HL145709 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SINGER, BENJAMIN HERSCHEL · 2020 to 2023
$1.6M
NHLBI NIH HHS R01 HL115138NHLBI NIH HHS R01 HL145709
6 · The paper itself

Abstract

Numerous human disorders can benefit from targeted, intravenous (IV) drug delivery. Polymeric nanoparticles have been designed to undergo systemic circulation and deliver their therapeutic cargo to target sites in a controlled manner. Poly(lactic-co-glycolic) acid (PLGA) is a particularly promising biomaterial for designing intravenous drug carriers due to its biocompatibility, biodegradability, and history of clinical success across other routes of administration. Despite these merits, PLGA remains markedly absent in clinically approved IV drug delivery formulations. A prominent factor in PLGA particles' inability to succeed intravenously may lie in the hydrophobic character of the polyester, leading to the adsorption of serum proteins (i.e., opsonization) and a cascade of events that end in their premature clearance from the bloodstream. PEGylation, or surface-attached polyethylene glycol chains, is a common strategy for shielding particles from opsonization. Polyethylene glycol (PEG) continues to be regarded as the ultimate "stealth" solution despite the lack of clinical progress of PEGylated PLGA carriers. This review reflects on some of the reasons for the clinical failure of PLGA, particularly the drawbacks of PEGylation, and highlights alternative surface coatings on PLGA particles. Ultimately, a new approach will be needed to harness the potential of PLGA nanoparticles and allow their widespread clinical adoption.

Indexed as

Drug CarriersNanoparticlesDrug Delivery SystemsHumansPolyethylene GlycolsPolylactic Acid-Polyglycolic Acid CopolymerPolymersDrug CarriersPolyethylene GlycolsPolylactic Acid-Polyglycolic Acid CopolymerPolymershydrophilicintravenous drug deliverypolyethylene glycolpoly(lactic-co-glycolic) acidstealth coatings

Identifiers

PMID35032406
PMCPMC9035064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.